Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia

Molecular Cancer Therapeutics

Volumn 5, Issue 8, 2006, Pages 1986-1994

  Efferth, Thomas ^a   Gillet, Jean Pierre ^b   Sauerbrey, Axel ^c   Zintl, Felix ^d   Bertholet, Vincent ^e   de Longueville, Françoise ^e   Remacle, Jose ^f   Steinbach, Daniel ^d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HELIOS KLINIKUM ERFURT   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e UNIVERSITY OF NAMUR   (Belgium)

^f Eppendorf Array Technologies   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ABC TRANSPORTER A2; ABC TRANSPORTER A3; ABC TRANSPORTER A4; ABC TRANSPORTER A5; ABC TRANSPORTER A6; ABC TRANSPORTER A7; ABC TRANSPORTER A8; ABC TRANSPORTER B10; ABC TRANSPORTER B11; ABC TRANSPORTER B2; ABC TRANSPORTER B3; ABC TRANSPORTER B4; ABC TRANSPORTER B6; ABC TRANSPORTER B7; ABC TRANSPORTER B8; ABC TRANSPORTER B9; ABC TRANSPORTER C1; ABC TRANSPORTER C2; ABC TRANSPORTER C3; ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT; DOXORUBICIN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN SUBUNIT; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VINBLASTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; DRUG SENSITIZATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; MALE; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN MICROARRAY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; T CELL LEUKEMIA; UPREGULATION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CHILD; CHILD, PRESCHOOL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, T-CELL, ACUTE; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MODELS, THEORETICAL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RNA INTERFERENCE; TUMOR CELLS, CULTURED;

EID: 33748367017     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0086     Document Type: Article

References (47)

1. Chauncey TR. Drug resistance mechanisms in acute leukemia. Curr Opin Oncol 2001;13:21-6.
2. Efferth T, Osieka R. Clinical relevance of the MDR-1 gene and its gene product, P-glycoprotein, for cancer chemotherapy: a meta-analysis. Tumor Diagn Ther 1993;14:238-43.
3. Sonneveld P, List AF. Chemotherapy resistance in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001;14:211-33.
4. Sauerbrey A, Zintl F, Volm M. P-glycoprotein and glutathione S-transferase pi in childhood acute lymphoblastic leukaemia. Br J Cancer 1994;70:1144-9.
5. Tafuri A, Sommaggio A, Burba L, et al. Prognostic value of rhodamine-efflux and MDR1/P-170 expression in childhood acute leukemia. Leuk Res 1995;19:927-31.
6. Dhooge C, de Moerloose B, Laureys G, et al. P-glycoprotein is an independent prognostic factor predicting relapse in childhood cute lymphoblastic leukaemia: results of a 6-year prospective study. Br J Haematol 1999;105:676-83.
7. Wattel E, Lepelley P, Merlat A, et al, Expression of the multidrug resistance P glycoprotein in newly diagnosed adult acute lymphoblastic leukemia: absence of correlation with response to treatment. Leukemia 1995;9:1870-4.
8. den Boer ML, Pieters R, Kazemier KM, et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998;91:2092-8.
9. Kanerva J, Tiirikainen MI, Makipernaa A, et al. Initial P-glycoprotein expression in childhood acute lymphoblastic leukemia: no evidence of prognostic impact in follow-up. Pediatr Hematol Oncol 2001;18:27-36.
10. Efferth T. The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr Mol Med 2001;1:45-65.
11. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
12. Gillet JP, Efferth T, Steinbach D, et al. Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res 2004;64:8987-93.
13. Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589-601.
14. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000;95:3310-22.
15. Schrappe M, Reiter A, Harbott J, et al. Improved risk-adapted treatment of childhood ALL with a new stratification system based on early response, genetics, age, and WBC: First interim analysis of trial ALL-BFM 95 [abstract 2999]. Blood, 2001;98:718a.
16. de Longueville F, Atienzar FA, Marcq L, et al. Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytes. Toxicol Sci 2003;75: 378-92.
17. de Longueville F, Surry O, Meneses-Lorente G, et al. Gene expression profiling of drug metabolism and toxicology markers using a low-density DNA microarray. Biochem Pharmacol 2002;64:137-49.
18. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e4S.
19. Rubinstein LV, Shoemaker RH, Paull KD, et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990;82:1113-38.
20. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-44.
21. Staunton JE, Slonim DK, Collar HA, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 2001;98:10787-92.
22. Szakacs G, Annereau JP, Lababidi S, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004;6:129-37.
23. Wosikowski K, Johnson K, Paull KD, Myers TG, Weinstein JN, Bates SE. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst 1997;89:1505-15.
24. Vulevic B, Chen Z, Boyd JT, et al. Cloning and characterization of human adenosine 5′-triphosphate-binding cassette, sub-family A, transporter 2 (ABCA2). Cancer Res 2001;61:3339-47.
25. Boonstra R, Timmer-Bosscha H, van Echten-Arends J, et al. Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation. Br J Cancer 2004;90:2411-7.
26. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004;101:14228-33.
27. Wulf GG, Modlich S, Inagaki N, et al. ABC transporter ABCA3 is expressed in acute myeloid leukemia blast cells and participates in vesicular transport. Haematologica 2004;69:1395-7.
28. Zhang JP, Ying K, Xiao ZY, et al. Analysis of gene expression profiles in human HL-60 cell exposed to cantharidin using cDNA microarray. Int J Cancer 2004;108:212-8.
29. Yasui K, Mihara S, Zhao C, et al. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 2004;64:1403-10.
30. Yamano G, Funahashi H, Kawanami O, et al. ABCA3 is a lamellar body membrane protein in human lung alveolar type II cells. FEBS Lett 2001;508:221-5.
31. Marie JP, Legrand O. MDR1/P-GP expression as a prognostic factor in acute leukemias. Adv Exp Med Biol 1999;457:1-9.
32. Wuchter C, Leonid K, Ruppert V, et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000;85:711-21.
33. Goasguen JE, Dossot JM, Fardel O, et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993;81:2394-8.
34. Volm M, Zintl F, Edler L, Sauerbrey A. Prognostic value of protein kinase C, proto-oncogene products and resistance-related proteins in newly diagnosed childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1997;28:117-26.
35. Kanerva J, Tiirikainen M, Makipernaa A, et al. Multiple drug resistance mediated by P-glycoprotein is not a major factor in a slow response to therapy in childhood ALL. Pediatr Hematol Oncol 1998;15:11-21.
36. Den Boer ML, Pieters R, Kazemier KM, et al. Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia. Leukemia 1999;13:2023-30.
37. Dhooge C, De Moerloose B, Laureys G, et al. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study. Br J Haematol 1999;105:676-83.
38. Tafuri A, Gregorj C, Petrucci MT, et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2002;100:974-81.
39. De Moerloose B, Swerts K, Benoit Y, et al. The combined analysis of P-glycoprotein expression and activity predicts outcome in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 2003;20:381-91.
40. Efferth T, Sauerbrey A, Steinbach D, et al. Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. Int J Oncol 2003;23:509-17.
41. Kakihara T, Tanaka A, Watanabe A, et al. Expression of multidrug resistance-related genes does not contribute to risk factors in newly diagnosed childhood acute lymphoblastic leukemia. Pediatr Int 1999;41: 641-7.
42. Damiani D, Michelutti A, Michieli M, et al. P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia. Br J Haematol 2002;116: 519-27.
43. Sauerbrey A, Voigt A, Wittig S, Hafer R, Zintl F. Messenger RNA analysis of the multidrug resistance related protein (MRP1) and the lung resistance protein (LRP) in de novo and relapsed childhood acute lymphoblastic leukemia. Leuk Lymphoma 2002;43:875-9.
44. Sauerbrey A, Sell W, Steinbach D, Voigt A, Zintl F. Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia. Br J Haematol 2002;118:147-50.
45. Steinbach D, Wittig S, Cario G, et al. The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood 2003;102:4493-8.
46. Suvannasankha A, Minderman H, O'Loughlin KL, et al. Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival. Br J Haematol 2004;127:392-8.
47. Tyzack JK, Wang X, Belsham GJ, Proud CG. ABC50 interacts with eukaryotic initiation factor 2 and associates with the ribosome in an ATP-dependent manner. J Biol Chem 2000;275:34131-9.